Table 3.

Comparison of clinical characteristics in survival and non-survival groups in 52 children with P. aeruginosa bacteremia

Characteristics	Non-survival (n = 12)	Survival (n = 40)	P values
Basic information
Age(years) (median, IQR)	1.55(0.21–9.80)	1.79(0.44–9.01)	0.373
Male (n, %)	8(66.7%)	24(60.0%)	0.938
Weight (kilogram) (median, IQR)	10.00(4.85–29.88)	11.25(7.00–27.00)	0.521
Underlying diseases
Hematologic malignancies (n, %)	2(16.7%)	14(35.0%)	0.395
Congenital heart disease (n, %)	1(8.3%)	6(12.5%)	1.000
Underlying conditions
Immunosuppression (n, %)	5(41.7%)	21(52.5%)	0.743
Neutropenia (n, %)	8(66.7%)	16(40.0%)	0.195
Hypoalbuminemia (n, %)	9(75.0%)	13(32.5%)	0.023*
Complications
Pneumonia (n, %)	3(25.0%)	6(15.0%)	0.129
Meningitis (n, %)	2(16.7%)	3(7.5%)	0.699
Peritonitis (n, %)	0(0.0%)	3(7.5%)	0.333
Origins of infection
Respiratory tract (n, %)	6(50.0%)	16(40.0%)	0.740
Primary bacteremia (n, %)	1(8.3%)	6(15.0%)	0.911
Vascular-catheter related infection (n, %)	1(8.3%)	7(17.5%)	0.752
Soft tissue infection (n, %)	3(25.3%)	5(12.5%)	0.551
Gastrointestinal infection (n, %)	1(8.3%)	4(10.0%)	1.000
Post-surgery or-procedure bacteremia (n, %)	0(0.0%)	2(5.0%)	0.434
Intensive unit care (n, %)	6(50.0%)	14(35.0%)	0.500
Nosocomial infection (n, %)	4(33.3%)	18(45.0%)	0.701
Pittsburgh bacteremia scores (median, IQR)	4.50(1.25–7.25)	1.00(1.00–3.75)	0.043*
Antibiotics administration before blood culture (n, %)	7(58.3%)	24(60.0%)	1.000
Inappropriate empirical antimicrobial therapy (n, %)	5(41.7%)	9(22.5%)	0.267
TTP (median, IQR)	15.19(11.21–18.24)	19.42(16.92–20.97)	0.005*
Length of hospitalization days (median, IQR)	2.86(2.07–28.08)	26.44(19.80–44.63)	0.002*
Multi-drug resistance bacteria (n, %)	0(0.0%)	4(10.0%)	0.259
Septic shock (n, %)	7(58.3%)	8(20.0%)	0.025*

* Indicates statistical significant results, P<0.05